Sudeep Pharma IPO Review – Should You Apply or Avoid?

The Sudeep Pharma IPO is set to hit the market with strong attention from both retail and institutional investors. As one of India’s leading manufacturers of pharmaceutical excipients, the company has demonstrated consistent growth, strong profitability, and significant export potential. With healthcare and generic formulation demand rising globally, this IPO is among the most discussed upcoming IPOs in India 2025.

Sudeep Pharma IPO Details

Particulars	Details
IPO Opening Date	21 November 2025
IPO Closing Date	25 November 2025
Allotment Date	26 November 2025
Listing Date	28 November 2025
Price Band	₹563 – ₹593 per share
Lot Size	25 shares
Minimum Investment (Retail)	₹14,825 ( 1 lot )
Maximum Investment (Retail)	₹1,92,725 ( 13 lots )
Total Issue Size	~₹895 crore
Fresh Issue	₹95 crore
Offer for Sale (OFS)	₹800 crore

About the Company

Sudeep Pharma is a leading manufacturer of calcium-based pharmaceutical excipients, supplying essential ingredients used in drug formulations. Its product range includes:

• Calcium carbonate
• Calcium citrate
• Calcium phosphate variants
• Specialty mineral-based excipients used in tablets, capsules, nutraceuticals, and supplements

The company follows a B2B business model, catering to domestic pharmaceutical giants as well as multiple international clients. With manufacturing units in Gujarat and a strong emphasis on quality, it has established long-term customer relationships in India, Europe, and regulated markets.

Key Management

Founder & Managing Director – Sujit Bhayani Over 30 years of experience in chemicals and excipient manufacturing.

•  Whole-Time Director – Ajay Shrirang Kandelkar
• Leads operations, strategy, and product development.
• Senior leadership comprises experts in R&D, quality control, and global compliance standards.

Financials Snapshot

Sudeep Pharma has delivered steady performance over the past few years:

Financial Year	Revenue (₹ Cr)	Profit After Tax (₹ Cr)
FY 2024	465.38	133.15
FY 2025	511.33	138.69
Q1 FY 2026	124.9	31.27

Key Highlights

• Strong PAT margins (~27.63% in FY25)
• Low debt-to-equity (0.20)
• 10%+ revenue growth year-on-year
• Strong cash flow and capital efficiency

Objectives of the Issue

Funds from the Fresh Issue of ₹95 crore will be used for:

• ₹75.81 crore for machinery procurement at the Nandesari Facility I
• Capacity expansion and modernization
• Working capital
• General corporate purposes

Industry / Sector Outlook

India is the world’s third-largest pharmaceutical producer, and demand for specialty excipients is increasing due to:

• Rising generic and OTC drug consumption
• Growth in nutraceutical and supplement categories
• Higher global outsourcing from India
• Increasing regulatory focus on high-purity excipients

This positions Sudeep Pharma strongly within an expanding niche segment.

Strengths

Market leader in calcium-based excipients with strong brand credibility

• Consistent financial growth with high margins
• Export-driven expansion, diversifying revenue streams
• Low leverage, offering financial stability

Also Read: NPS vs Mutual Funds vs PPF vs FDs – Which is Best for Your Retirement in 2025?

Risks / Challenges

Raw material price volatility may impact margins

• Dependence on pharma sector cycles, which can fluctuate
• Stringent regulatory approvals for global markets
• Rising competition from domestic and Asian specialty chemical companies

Peer Comparison / Competitors

Sudeep Pharma competes with established excipient and specialty chemical manufacturers such as:

• Loba Chemie
• Anmol Chemicals
• Other regional calcium derivative producers

The company differentiates itself through product quality and long-term client relationships.

Valuation

Based on FY25 earnings and the upper price band of ₹593, the valuation appears fair relative to specialty chemical peers. Strong profitability and export exposure further support the valuation, though investors should assess final EPS and P/E ratios before subscribing.

Conclusion

The Sudeep Pharma IPO offers investors an opportunity to participate in a high-margin, growing pharmaceutical support industry. Strong financials, leadership position, and expansion plans are positives. However, regulatory dependence and raw material risks must be considered.

Final Recommendation: Apply or Avoid?

The company’s stable growth, robust margins, low debt, and niche market leadership make the IPO attractive, especially for long-term investors seeking exposure to specialty chemicals and pharma supply chains.